drugset / Trial / NCT06641089
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.
Timeline
- Start
- 2024-10-15
- Primary completion
- 2027-01-15
- Completion
- 2027-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | M1095 | Protein / enzyme biologic | 60 mg | Subcutaneous |
| Subject | M1095 | Protein / enzyme biologic | 120 mg | Subcutaneous |
| Comparator | Risankizumab | Monoclonal antibody | — | Subcutaneous |